A positive amyloid positron emission tomography (PET) scan, regardless of tau pathology and neurodegeneration, indicates the participant has AD pathologic change, distinguishing those on the AD continuum from the ones with similar phenotypes but without underlying biological AD pathology. This evidence concerns the gene MAPT and Alzheimer disease.